TNGX vs DBVT vs IMVT vs AZN

For growth investors, Tango Therapeutics, Inc.

(TNGX) is the stronger pick with 48. 3% revenue growth year-over-year, versus 8. 6% for AstraZeneca PLC (AZN). AstraZeneca PLC (AZN) offers the better valuation at 27. 9x trailing P/E (17. 7x forward), making it the more compelling value choice. Analysts rate Tango Therapeutics, Inc. (TNGX) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Tango Therapeutics, Inc.

(TNGX) delivered a total return of +117. 2%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: AZN returned +268. 6% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AstraZeneca PLC (AZN) is the lower-risk stock at 0.

67β versus Tango Therapeutics, Inc. 's 1. 81β — meaning TNGX is approximately 170% more volatile than AZN relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 61% for AstraZeneca PLC — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Tango Therapeutics, Inc.

(TNGX) is pulling ahead at 48. 3% versus 8. 6% for AstraZeneca PLC (AZN). On earnings-per-share growth, the picture is similar: AstraZeneca PLC grew EPS 190. 7% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Over a 3-year CAGR, TNGX leads at 35. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

AstraZeneca PLC (AZN) is the more profitable company, earning 17.

5% net margin versus -162. 9% for Tango Therapeutics, Inc. — meaning it keeps 17. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AZN leads at 23. 4% versus -178. 4% for TNGX. At the gross margin level — before operating expenses — TNGX leads at 96. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for DBVT: 131.

8% to $46. 33.

In this comparison, AZN (1.

8% yield) pays a dividend. TNGX, DBVT, IMVT do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AstraZeneca PLC (AZN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

67), 1. 8% yield, +268. 6% 10Y return). Tango Therapeutics, Inc. (TNGX) carries a higher beta of 1. 81 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (AZN: +268. 6%, TNGX: +129. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TNGX is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; IMVT is a small-cap quality compounder stock; AZN is a large-cap quality compounder stock. AZN pays a dividend while TNGX, DBVT, IMVT do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.